Table 1 Baseline features of the study population according to the outcome of SBT
From: Application of heart-rate variability in patients undergoing weaning from mechanical ventilation
Characteristics | Successful SBT | Failed SBT | P value |
|---|---|---|---|
(n = 77) | (n = 24) | ||
Age, years | 65 ± 18 | 71 ± 16 | 0.186 |
 ≧65 years | 45 (58) | 17 (71) | 0.276 |
Male sex | 54 (70) | 12 (50) | 0.070 |
Body mass index | 22 ± 4 | 23 ± 4 | 0.378 |
APACHE II | 17 ± 6 | 16 ± 7 | 0.767 |
Comorbidities | |||
 Cerebrovascular disease | 16 (21) | 4 (17) | 0.776 |
 COPD | 19 (25) | 7 (29) | 0.660 |
 Heart failure | 3 (4) | 1 (4) | 0.999 |
 Liver cirrhosis | 4 (5) | 1 (4) | 0.999 |
 End-stage renal disease | 6 (8) | 2 (8) | 0.999 |
 Diabetes mellitus | 26 (34) | 6 (25) | 0.420 |
 Hypertension | 30 (39) | 8 (33) | 0.619 |
 Coronary artery disease | 5 (7) | 3 (13) | 0.391 |
Cause of acute respiratory failure | |||
 Pneumonia | 34 (44) | 15 (63) | 0.116 |
 Sepsis | 15 (20) | 3 (13) | 0.551 |
 Acute exacerbation of COPD | 3 (4) | 1 (4) | 0.999 |
 Gastrointestinal bleeding | 10 (13) | 1 (4) | 0.452 |
 Lung edema | 4 (5) | 1 (4) | 0.999 |
 Neurologic disease | 6 (8) | 3 (13) | 0.440 |
 Others | 5 (7) | 0 (0) | 0.335 |
Time to first SBT, hours | 96 ± 103 | 94 ± 71 | 0.931 |
Medications | |||
 β2 agonist | 28 (36) | 17 (71) | 0.003 |
 Anticholinergic | 22 (29) | 16 (67) | 0.001 |
 ACEI/ARB | 8 (10) | 2 (8) | 0.999 |
 CCB | 27 (35) | 13 (54) | 0.095 |
 β blocker | 11 (14) | 3 (13) | 0.999 |